Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/bmt.2009.6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nilotinib boosts the efficacy of anti-PDL1 therapy in colorectal cancer by restoring the expression of MHC-I.
J Transl Med
August 2024
Department of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510655, Guangdong, China.
Article Synopsis
- Immune checkpoint inhibitors (ICIs) are transforming cancer treatment, but many colorectal cancer (CRC) patients still don't respond; improving MHC-I expression could enhance tumor immunity and ICI effectiveness.
- Researchers tested drug candidates, particularly nilotinib, using various techniques to confirm its ability to boost MHC-I expression and enhance CD8 T-cell activity against CRC.
- Nilotinib increases MHC-I levels through the cGAS-STING-NF-κB pathway, lowers MHC-I degradation by inhibiting PCSK9, and the study suggests combining it with anti-PDL1 therapy may improve CRC treatment outcomes.*
Impact of Tyrosine Kinase Inhibitors (TKIs) on Growth in Children and Adolescents with Chronic Myeloid Leukemia: A Systematic Review.
Curr Pharm Des
October 2024
Program of Postgraduate Studies "Adolescent Medicine and Adolescent Health Care", School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece.
Background: Chronic Myeloid Leukemia (CML) is a rare myeloproliferative disease in childhood. Treatment in CML includes Tyrosine Kinase Inhibitors (TKIs), which inhibit the cytoplasmic kinase BCR/ABL. Tyrosine kinases play a key role in the secretion of growth hormone and insulin-like growth factor 1 (IGF-1).
View Article and Find Full Text PDFDevelopment of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia.
J Clin Exp Hematop
March 2023
Department of Internal Medicine, Nippon Koukan Hospital, Kanagawa, Japan.
We present the case of an 85-year-old male patient diagnosed with human herpesvirus 8 (HHV8)-negative effusion-based lymphoma (EBL) that developed from long-lasting pleural effusion (PE) induced by dasatinib treatment for chronic myeloid leukemia (CML). After the onset of this disorder, dasatinib treatment was discontinued and drainage was performed to regress the effusion. The major molecular response (MMR) was thus lost.
View Article and Find Full Text PDFRosmarinic Acid Attenuates Rotenone-Induced Neurotoxicity in SH-SY5Y Parkinson's Disease Cell Model through Abl Inhibition.
Nutrients
August 2022
Center for Mitochondria and Healthy Aging, College of Life Sciences, Yantai University, Yantai 264005, China.
Rosmarinic acid (RA) is a natural polyphenolic compound with antioxidative property. With the present study, we aimed to evaluate the neuroprotective role of RA on Parkinson's disease using rotenone induced SH-SY5Y cell model of Parkinson's disease, the underlying mechanism of action of RA was also investigated. Cell viability, cell morphology, apoptosis, signaling protein phosphorylation and expression, cellular reactive oxygen species (ROS) production, ATP content, and mitochondrial membrane potential were tested in SH-SY5Y cells.
View Article and Find Full Text PDFGenome‑wide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitor‑resistant CML cells.
Oncol Rep
August 2022
Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig‑Holstein, Campus Kiel, D-24105 Kiel, Germany.
Although chronic myeloid leukemia (CML) can be effectively treated using BCR‑ABL1 kinase inhibitors, resistance due to kinase alterations or to BCR‑ABL1 independent mechanisms remain a therapeutic challenge. For the latter, the underlying mechanisms are widely discussed; for instance, gene expression changes, epigenetic factors and alternative signaling pathway activation. In the present study, ‑CML cell models of resistance against the tyrosine kinase inhibitors (TKIs) imatinib (0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!